CAINasdaq

Caris Life Sciences Inc.

Healthcare·Oncology·Commercial·Irving, TX, United States
Oncology

Caris Life Sciences Inc. (CAI): 3 pipeline candidates · ~29 mo cash runway. Updated within the last hour.

7.8/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway8.1

29.0 months

Financial Health8.6

D/E 0.96 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth5.9

3 candidates

Catalyst MomentumN/A

N/A

Insider Signal6.5

1 buy · 0 sells (180d)

A transparent, data-derived signal for Caris Life Sciences Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$5.1B

Cash

$819.9M

Quarterly Burn

$91.0M

Runway

29.0 mo

Revenue

$216.2M

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Nov 2028
Today~32 mo out
Catalyst within runway

Pipeline (3 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

198

Total value held

$1.95B

HolderSharesValue
fmr llc30,785,585$550.4M
coatue management llc9,819,992$175.6M
braidwell lp8,009,447$143.2M
vanguard capital management llc6,658,042$119.0M
blackrock, inc.4,857,112$86.8M
vanguard portfolio management llc3,758,462$67.2M
neuberger berman group llc3,590,586$64.2M
jpmorgan chase & co3,460,215$58.3M
orbimed advisors llc2,806,811$50.2M
ubs group ag2,745,811$49.1M

Showing top 10 of 198 institutional holders of Caris Life Sciences Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·CEO: Dr. David Dean Halbert M.D.

Frequently asked questions

How many drug candidates are in Caris Life Sciences Inc.'s pipeline?

Caris Life Sciences Inc. (CAI) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Caris Life Sciences Inc.'s lead drug candidate?

Caris Life Sciences Inc.'s most advanced tracked candidate is caris assure (Preclinical) for Minimal residual disease tracking and treatment monitoring.

What is Caris Life Sciences Inc.'s cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Caris Life Sciences Inc. has approximately 29.0 months of cash runway.

What is Caris Life Sciences Inc.'s market capitalization?

Caris Life Sciences Inc.'s market capitalization is approximately $5.1B.

Who is the CEO of Caris Life Sciences Inc.?

Dr. David Dean Halbert M.D. is the chief executive officer of Caris Life Sciences Inc. (CAI).

Get the full picture on Caris Life Sciences Inc.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.